2026-09-09
This head‑to‑head comparative study, backed by solid and transparent data, unequivocally demonstrates that China‑developed cryoprotectants already possess significant international competitiveness in core performance. This not only reflects Yinfeng's technological prowess but also serves as a compelling testament to China's cryobiomedicine field transitioning from "following" to "running alongside" global leaders—earning international discourse power through scientific evidence.
2026-05-18
Beyond organ transplantation, this non-toxic low-temperature preservation framework can be extended to long-term storage of stem cells, reproductive cells, and germplasm resources of endangered species, providing a universal technological foundation for biobanks, regenerative medicine, and other fields.
2026-04-29
The clinical value of this approach lies in its extremely simple operation. It requires no specialized cryopreservation solutions or complex equipment, using only GMP‑grade compliant cytokines that can be removed by routine washing after pretreatment, posing no additional safety risks to patients and enabling rapid integration into existing cell production and cryopreservation workflows. As the large‑scale manufacturing of NK cells derived from umbilical cord blood and iPSCs becomes increasingly mature, combining this cryopreservation technology holds the potential to significantly reduce cell therapy costs and improve accessibility, opening new avenues for immunotherapy in hematological malignancies and solid tumors.
2026-03-16
In science fiction, human cryopreservation and resuscitation are often regarded as a "time capsule" to the future. Now, this concept has achieved a milestone breakthrough in the laboratory—scientists have for the first time successfully cryopreserved adult mouse brain slices in liquid nitrogen at -196°C and restored multiple key neural functions, including learning and memory mechanisms, after rewarming. This achievement blazes a brand-new trail for basic neuroscience research and organ preservation technology.
2025-08-15
Good News! Three Organoid Cryopreservation Technologies of Our Team Accepted for National Patents
In the era of rapid development of organoid research, achieving long - term stable preservation while maintaining biological activity and functional integrity remains a crucial bottleneck restricting the clinical translation of this technology and its application in drug R & D. Recently, three technological inventions by the research team of Yinfeng Low - Temperature Medical Research Center were accepted by the National Intellectual Property Administration. These three technologies focus on the challenges of organoid cryopreservation and cover the key steps in the entire process of organoid vitrification preservation, offering a more efficient and reliable solution for safeguarding biological samples in organoid research.
2025-07-03
On June 25, 2025, the team led by Professor Wang Huiying and Dr. Jin Bo from Shenzhen Hospital of Beijing University of Chinese Medicine collaborated with Shandong Yinfeng Life Science Research Institute to develop the "ovarian dual activation" technology. Through this technology, patients with POI (primary ovarian insufficiency) underwent intra - operative freeze - thaw activation of ovarian tissue. After intra - operative transplantation, a baby was born, and both the mother and the baby are healthy and safe.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
